BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioMarin Pharma (BMRN) Tops Q1 EPS by 19c, Offers FY Guidance
April 29, 2021 4:13 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.09, $0.19 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $486 million versus the consensus estimate of $446.45 million.
GUIDANCE:
BioMarin Pharma sees FY2021 revenue of $1.75-1.85 billion, versus the consensus of... More
